Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575094 | 0.91 | — | — | |
| SCHEMBL11530469 | 0.90 | ALDH1A1 (0.35) | ALDH1A1TP53TSHR | |
| SCHEMBL15180219 | 0.89 | TSHR (0.41) | ALDH1A1TSHRKMT2A | |
| SCHEMBL9303937 | 0.88 | SOAT1 (0.46) | ALDH1A1TP53SOAT1 | |
| SCHEMBL575192 | 0.87 | — | — | |
| SCHEMBL9512898 | 0.87 | — | — | |
| SCHEMBL10836973 | 0.87 | ALDH1A1 (0.43) | ALDH1A1TSHRSOAT1 | |
| SCHEMBL9215552 | 0.84 | TSHR (0.35) | ALDH1A1TSHR | |
| SCHEMBL575123 | 0.83 | — | — | |
| SCHEMBL4293436 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119447514-A | Biphase electrolyte and electrochemical device | 清华大学深圳国际研究生院 | 2025-02-14 | — | — | CN | claimed |
| WO-2024191025-A1 | COSMETIC COMPOSITION COMPRISING CAPSULES OR BEADS | 한국콜마주식회사 | 2024-09-19 | — | — | WO | claimed |
| CN-116144055-A | Biaxially oriented crosslinked polyethylene film and preparation method thereof | 国家能源投资集团有限责任公司 | 2023-05-23 | — | — | CN | claimed |
| CN-108659527-B | High-strength glass fiber composite material and preparation method thereof | 元源新材料有限公司 | 2021-01-05 | — | — | CN | claimed |
| CN-108467579-B | Organic glass fiber composite material and preparation method thereof | 贵州安顺开发区埃维森航空科技开发有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-9907796-B2 | Methods of treating tumoral diseases, or bacterial or viral infections | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | SPHAERA PHARMA PTE. LTD. (SG) | 2017-01-05 | — | — | US | claimed |
| WO-2016151508-A1 | METHOD AND APPARATUS FOR THE PRODUCTION OF DIARYL CARBONATE | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2016-09-29 | — | — | WO | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-4059610-A | Process for preparing isocyanic acid derivatives | KAO SOAP CO., LTD. (JA) | 1977-11-22 | — | — | US | claimed |
| US-4028299-A | CATALYST-FREE, LIQUID CARBONATE AS MODIFIER | THE DOW CHEMICAL COMPANY (US) | 1977-06-07 | — | — | US | claimed |
| US-3983066-A | Solid, rapid setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | claimed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-3956221-A | Rapid setting non-elastomeric polyurethane compositions containing a non-hydroxyl containing ester-modified polyoxylkylene compound | THE DOW CHEMICAL COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | ALDH1A1 524/4885TP53 3939/4885TSHR 3151/4885 |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | POLI, RNASE1, VHL | ALDH1A1 1777/4885TP53 73/4885TSHR 4292/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | ALDH1A1 1607/4885TP53 3975/4885TSHR 2320/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | ALDH1A1 2478/4885TP53 5/4885TSHR 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.